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ABSTRACT 1 
D-Fagomine is an iminosugar found in buckwheat that is capable of inhibiting the adhesion of 2 
potentially pathogenic bacteria to epithelial mucosa and of reducing postprandial blood glucose 3 
concentration. This paper evaluates the excretion and metabolism of orally administered D-4 
fagomine in rats and compares outcomes with the fate of 1-deoxynojirimycin. D-Fagomine and 1-5 
deoxynojirimycin show similar absorption and excretion kinetics. D-Fagomine is partly absorbed 6 
(41-84%, dose 2 mg/kg body weight) and excreted in urine within 8 h while non-absorbed fraction 7 
is cleared in feces within 24 h. D-Fagomine is partially methylated (about 10% in urine and 3% in 8 
feces). The concentration of D-fagomine in urine from 1 to 6 h after administration is higher than 10 9 
mg/L, the concentration that inhibits adhesion of Escherichia coli. Orally administered D-fagomine 10 
is partially absorbed and then rapidly excreted in urine were it reaches a concentration that may be 11 
protective against urinary tract infections. 12 
13 
Keywords. D-fagomine, 1-deoxynojirimycin, metabolism, Escherichia coli, urinary tract, mass 14 
spectrometry. 15 
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INTRODUCTION 17 
D-Fagomine and 1-deoxynojirimycin (DNJ) are polyhydroxylated piperidines, also known as 18 
iminocyclitols, azasugars or iminosugars, that are synthesized by various plants and 19 
microorganisms as secondary metabolites 1,2. D-fagomine and DNJ can be found in foodstuffs such 20 
as bread, pasta and biscuits made from buckwheat 3, and tea, snacks and biscuits made from 21 
mulberry 4. Both of these iminocyclitols are glycosidase inhibitors with the capacity to reduce the 22 
postprandial glycemic response after oral administration of either sucrose or starch to rats and 23 
humans 58. As D-fagomine and DNJ reduce the elevation of postprandial blood glucose they can be 24 
used as dietary supplements or functional food components to help maintain short-term 25 
homeostasis of blood glucose levels 9. More recent observations have revealed that iminocyclitols 26 
may modify the composition of the gut microbiota by inhibiting bacterial adhesion to the intestinal 27 
mucosa 7. It has been suggested that D-fagomine counteracts the short term metabolic alterations 28 
triggered by a high-energy-dense diet in rats 10, at least in part through the reduction of a diet 29 
induced excess of gut Enterobacteriales 11. Thus, D-fagomine might also be administered to prolong 30 
maintenance of metabolic homeostasis.  31 
Absorption, distribution, metabolism and excretion (ADME) studies in animals and humans have 32 
been published of naturally and non-naturally occurring bioactive iminocyclitols such as DNJ, N-33 
methyl-DNJ, 1-deoxymannojirimycin (DMJ), 1,4-dideoxy-1,4-imino-d-arabinitol (DAB), N-34 
hydroxyethyl-DNJ (miglitol or glyset), N-butyl-DNJ (miglustat or zavesca) 1222. In rats, DNJ is 35 
poorly absorbed in a dose-dependent manner, distributed in the intact form and rapidly excreted in 36 
urine 15,16,18,23. The absorption and distribution of D-fagomine alone has never been reported. When 37 
administered as a minor component of an extract from mulberry twigs (Ramulus Mori, Chinese 38 
medicine) the D-fagomine absorption rate profile is similar to that of DNJ 21.  39 
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Bioanalytical methods for iminocyclitols have recently been reviewed 24. Pharmacokinetics is 40 
effectively evaluated using radiolabeled derivatives. The technique is extremely sensitive but would 41 
fail to identify any putative transformation as a result of metabolism. More selective and safe 42 
hyphenated bioanalytical methods have also been developed. In particular, iminocyclitols are 43 
analyzed by hydrophilic interaction or cation exchange liquid chromatography coupled to different 44 
mass spectrometry detectors (single quadrupole (Q), triple quadrupole (QqQ), quadrupole-ion trap 45 
(QTrap), or time-of-flight (TOF)) 1,1519,22.  46 
The aim of this paper is to evaluate D-fagomine metabolism and excretion, and compare the results 47 
with those for DNJ: an iminocyclitol with putatively similar behavior.  48 
49 
MATERIALS AND METHODS 50 
Reagents 51 
A D-fagomine standard (assay > 98%) was provided by Bioglane (Barcelona, Spain). DNJ was 52 
from Carbosynth (Berkshire, UK). DMDP (2,5-hydroxymethyl-3,4-dihydroxypyrrolidine), the 53 
internal standard, was purchased from IRL (Lower Hutt, New Zealand). Lichrosolv grade 54 
methanol, together with analytical grade acetic acid and ammonium hydroxide were obtained from 55 
Merck (Darmstadt, Germany). HPLC-grade water (Millipore type I water from Merck) was used to 56 
prepare all of the aqueous solutions. Solid-phase extraction (SPE) cartridges for sample purification 57 
were Spe-ed, SCX (strong cation exchange) cartridges, 100 mg/mL from Applied Separations 58 
(Allentown, PA, USA). Nylon filters (0.45 m) were obtained from Scharlab (Sentmenat, Spain). 59 
Microvette® CB 300 K2E Di-kalium-EDTA tubes were from Sarstedt (Nümbrecht, Germany), the 60 
gastric probe was from Harvard Apparatus (Holliston, MA, USA); and 25 G needles were from 61 
Novico Médica (Barcelona, Spain).  62 
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Animals, diets and in vivo tests 63 
Eighteen 8-week-old female SpragueDawley rats (Janvier, Le Genest-St-Isle, France) were housed 64 
under controlled conditions of stable humidity (50% ± 10%), and temperature (22 ºC ± 2 ºC) with a 65 
12 h light  12 h dark cycle. To minimize circadian rhythm effects, all rat handling was carried out 66 
in the morning. After overnight fasting, the rats were divided into six groups which were given 67 
single doses of D-fagomine or DNJ, administered as aqueous solutions (5 mL/kg body weight) 68 
using a gastric probe. Each group received 2.0, 10, or 100 mg/kg body weight of D-fagomine or 69 
DNJ. The rats were then placed in metabolic cages to collect urine and feces 1, 2, 4, 6, 8 and 24 h 70 
after administration. Samples were kept at 80 ºC until analysis. After that, the rats were placed in 71 
standard cages and the remaining feces were collected by abdominal massage 48 h after 72 
administration. The handling of the animals was in full accordance with the European Union 73 
guidelines for the care and management of laboratory animals, and the pertinent permission was 74 
obtained from the CSIC Subcommittee for Bioethical Issues (ref. AGL2009-12 374-C03-03, 75 
CEEA-12-011, date of approval March 4th, 2013).  76 
Extraction and SPE clean-up 77 
After thawing, aliquots (60 L) of urine were extracted with 70% aqueous methanol (5 mL) using 78 
an orbital shaker (Intelli-mixer RM-2 device from Elmi; Riga, Latvia) for 20 min. Feces were cut 79 
longitudinally and the analytes were extracted from half of the sample also with 70% aqueous 80 
methanol (5 mL solvent/ 60 mg feces) using the orbital shaker for 20 min. After extraction the 81 
suspensions were centrifuged in a 5810R centrifuge from Eppendorf (Hamburg, Germany) for 3 82 
min at 8000 rpm and 20 ºC, filtered through a 0.45-m nylon filter (Phenomenex; Torrance, CA, 83 
USA) and the filtrates were diluted with water to a known volume in a volumetric flask (10 mL in 84 
the case of urine; variable in the case of feces). Cation exchange SPE cartridges were conditioned 85 
with HPLC-grade methanol (1 mL) and water (1 mL). Then aliquots from the previous step were 86 
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loaded onto the cartridges. The aliquot volumes were adjusted to equalize the response of the 87 
analysis (urine samples: 2500, 500 and 50 L from the groups administered the 2.0, 10 and 100 88 
mg/kg body weight doses respectively; feces samples: variable volumes depending on the dilution 89 
after the extraction step). SCX resin was then washed with water (4 mL) and vacuum-dried. Next, 90 
the analytes were eluted with 2 M aqueous NH4OH (500 L). The eluates were spiked with a 91 
DMDP solution in methanol (100 L, 5 mg/L). The solution was evaporated to dryness under a 92 
stream of N2 at 60°C and the residue was redissolved in water (500 L) and filtered through a 0.45-93 
m nylon filter.  94 
HPLC/ESI–QqQ-MS analysis 95 
Chromatography was carried out on an Acquity H class system (Waters; Milford, MA, USA) 96 
equipped with a quaternary pump and fitted with a TSK-Gel CM2SW cation exchange column (25 97 
cm×4.6 mm i.d., 5 m particle size) (Tosoh Bioscience; Tokyo, Japan). The injection volume was 5 98 
L, the column temperature 25 °C and the total analysis time 30 min. The target compounds were 99 
separated with a binary system: 50 mM NH4CH3COO (pH 8.5) / methanol (4:1), under isocratic 100 
conditions at a flow rate of 0.8 mL/min. Mass spectrometric analysis of the column effluent was 101 
carried out on a triple tandem quadrupole Xevo-TQ-S spectrometer (Waters). The ESI-MS/MS 102 
parameters were: positive polarity, a capillary voltage of 3 kV, a desolvation temperature of 600 ºC, 103 
a desolvation gas flow of 1000 L/h, 7 bar of nebulizer gas, with a cone voltage of 20-45 V 104 
depending on the analyte, and a collision energy of 20-30 V depending on the analyte (Table 1). 105 
Analysis was carried out in the multiple reaction monitoring mode (MRM) using the following 106 
quantification transitions: 164  80 (DMDP and DNJ), 148  86 (D-fagomine), 162  100 107 
(monomethyl-D-fagomine), 176  114 (dimethyl-D-fagomine), 190  128 (trimethyl-D-108 
fagomine), 178  94 (monomethyl-DNJ), 192  108 (dimethyl-DNJ), 206  122 (trimethyl-109 
DNJ). The retention times of the analytes were 4 min (DNJ), 5.5 min (DMDP), 7.5 min 110 
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(monomethyl-D-fagomine), 9 min (D-fagomine), 10 min (dimethyl-D-fagomine), 10.5 min 111 
(trimethyl-D-fagomine) and 3.7 (monomethyl-DNJ). To confirm the identity of the metabolites, 112 
their exact masses were obtained using high resolution (HR) ESItime of flight (TOF)-MS on an 113 
LCT Premier XE system (Waters) after HR separation using an HPLC Acquity system (Waters) 114 
fitted with a TSK-Gel CM2SW column. 115 
Standard solutions 116 
Stock standard solutions of 5 mg/L were prepared by dissolving D-fagomine, DNJ or DMDP (1.00 117 
mg) in methanol (20 mL) and then diluting 1:9 in methanol. All solutions were stored at 20 °C. To 118 
prepare the working standard solutions, the corresponding aliquots of the D-fagomine or DNJ stock 119 
solutions were mixed with the DMDP stock solution (100 L). The solvent was then evaporated to 120 
dryness under a stream of N2 and the residue was dissolved in water (500 L). These solutions were 121 
also stored at 20°C. The standard solutions were stable at this temperature for a period of at least 6 122 
months. 123 
Validation of the analytical method 124 
As ESI techniques often suffer from matrix effects, the linear MS responses of D-fagomine/DMDP 125 
and DNJ/DMDP dissolved in water and matrix-matched solutions were evaluated and the slopes 126 
were compared. To prepare the matrix-matched solutions, urine and feces of rats that had still not 127 
been administered the iminosugars were used. These samples were subjected to the extraction and 128 
purification steps described in the Extraction and SPE clean-up subsection. In the case of urine, 129 
2500 L of the extract (the aliquot that contains the highest amount of interfering compounds) were 130 
passed through the cartridge. The eluate obtained from the SCX resin was spiked with 100 L of a 131 
DMDP solution in methanol (5 mg/L), and with different volumes of a D-fagomine + DNJ solution 132 
in methanol (5 mg/L of both compounds) to prepare a calibration curve in the range 4  83 mg D-133 
fagomine/L urine or kg feces. Each solution was evaporated to dryness under a stream of N2 at 60 134 
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°C and the residue was redissolved in water (500 L) and then filtered through a 0.45-m nylon 135 
filter. Calibration curves were constructed by plotting AD-fagomine or DNJ/ADMDP against D-fagomine or 136 
DNJ concentration for each solvent. Then the SSE was calculated according to Eq. 1. An SSE value 137 
smaller than 100 means that the matrix causes signal suppression, and a higher value means that the 138 
matrix causes signal enhancement 25. 139 
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 × 100 [Eq. 1] 140 
In the assessment of linearity, calibration curves were plotted in the range 1.8  8300 mg/L and 8.3 141 
 8300 mg/L for D-fagomine and DNJ, respectively. Calibration curves with eleven calibration 142 
standards each were prepared across these ranges. All of the calibration standards were prepared 143 
using matrix matched solutions, and were spiked with the DMDP standard stock solution (100 L, 144 
5 mg/L). Linearity was evaluated for every analytical run batch to compensate for ESI variability. 145 
The concentration of the metabolites was expressed as DNJ of D-fagomine equivalents, due to the 146 
lack of commercial standards. 147 
A precision and trueness study was carried out with the different matrices. The recovery study was 148 
performed by spiking the matrices with D-fagomine at three different concentrations (67, 330 and 149 
3300 mg/L in urine; and 130, 670 and 6700 mg/kg in feces) in triplicate in three different days. 150 
Three standard solutions of D-fagomine were prepared in methanol (200, 1000 and 10000 mg/L), 151 
one for each of the three spiking levels. In the case of urine, the solvent of an aliquot (20 L) of the 152 
corresponding standard was evaporated and the residue containing D-fagomine was suspended in 153 
the matrix under study (60 L of urine). In the case of feces, a portion (60 mg) was spiked with an 154 
aliquot (40 L) of the corresponding standard. The feces samples were processed 24 h after 155 
spiking, to ensure complete evaporation of the solvent. Next, thesamples were subjected to the 156 
purification step. After elution, the eluates were spiked with the DMDP standard stock solution 157 
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(100 L, 5 mg/L) to correct for ESI variability. The solution was evaporated to dryness under a 158 
stream of N2 at 60 °C and the residue was redissolved in water (500 L) and filtered through a 159 
0.45-m nylon filter. In parallel, the calibration curves were prepared using matrix-matched 160 
standards. Finally, the samples and the calibration standards were analyzed by LC-MS/MS. 161 
Recovery was determined by comparing the AD-fagomine/ADMDP signal obtained from the spiked 162 
samples with the AD-fagomine/ADMDP signal from the calibration standards. Precision was evaluated by 163 
calculating the RSDs obtained in within- and between-day recovery experiments. The limit of 164 
quantification (LOQ) was established as the concentration at which a recovery value similar to that 165 
of the trueness study was obtained with an RSD<20% when analyzing five spiked samples.   166 
167 
RESULTS AND DISCUSSION 168 
Set-up and validation of the analytical method 169 
The analytical method was adapted for biological fluids from  a previously described procedure 170 
developed for the analysis of plant sources (buckwheat and mulberry) 1. Modifications were 171 
introduced in the extraction step and, to improve selectivity and sensibility, triple quadrupole MS 172 
was used instead of single quadrupole MS. First, the MS parameters such as desolvation 173 
temperature, cone voltage or collision energy were optimized to improve better signal intensity for 174 
the analytes under study. Then, selectivity, sensibility and linearity were checked by preparing the 175 
D-fagomine and DNJ calibration curves using DMDP as an internal standard and two solvents: 176 
water and the matrix resulting from control urine or feces subjected to the extraction and SPE 177 
purification steps. The calibration curves generated with the two matrices showed significant signal 178 
suppression/enhancement (Table 2), so the calibration standards used from that point on were 179 
prepared using matrix-matched solutions. The assay response (area of the D-fagomine or DNJ peak 180 
divided by the area of the DMDP peak) to D-fagomine or DNJ concentration was linear (R2 > 0.99) 181 
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in the ranges under study (1.8  8300 mg/L and 8.3  8300 mg/L for D-fagomine and DNJ, 182 
respectively). Within-day and between-day precision and trueness were studied using samples of 183 
urine and feces spiked with D-fagomine. In the case of urine, the percentage recovery at the three 184 
concentrations assayed (96%) was homogeneous (RSD: 12%), which demonstrated the precision 185 
and trueness of the analytical procedure. The European Medicines Agency (EMEA) 26 recommends 186 
a recovery value (trueness) in the range 85%115% and a relative standard deviation value (RSD; 187 
precision) of under 15% for bioanalytical methods. In the case of feces, within-day recovery was 188 
47% (RSD: 10%): outside the EMEA suggested interval (85%-115%). Intra-day recovery was 51% 189 
(RSD: 14%), which demonstrated the validity of the method despite the low recovery. The results 190 
in this work are corrected for the recovery values. The LOQ values were 1.8 mg/L urine or kg 191 
feces, for D-fagomine; and 8.3 mg/L urine or kg feces, for DNJ. DNJ shows a higher LOQ value 192 
because its ionization in the MS detector was not as complete as that of D-fagomine. 193 
The results of the validation study show that the new methods met all the requirements for a 194 
bioanalytical process 26. The methods were selective; the response was linear in the working range; 195 
precision and trueness fell within the recommended range except for feces recovery; and the LOQ 196 
was much lower than the D-fagomine and DNJ concentrations found after the maximum excretion 197 
period. The methods were successfully applied to the determination of D-fagomine, DNJ and their 198 
metabolites in the urine and feces of rats fed D-fagomine or DNJ. The identity of the compounds 199 
was confirmed by HPLC/ESIHR-TOF-MS with samples generated in a previous separate 200 
experiment by administration of 250 mg of iminocyclitol per kg body weight (Table 3).  201 
Absorption and excretion 202 
 The animals were administered 2.0, 10 or 100 mg/kg body weight of D-fagomine or DNJ (positive 203 
control). The dose of 2.0 mg/kg body weight corresponded to the dose of D-fagomine that reduced 204 
postprandial blood glucose concentration (20% reduction of the area under the curve between 0 and 205 
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120 min) after intake of glucose or starch 7. At this active concentration part of the administered D-206 
fagomine (0.2-0.4 mg) was absorbed and excreted in urine within 8 h, while the rest was recovered 207 
in feces within 24 h (Figure 1a and Table 4). Absorption appears to be limited due to saturation 208 
after a total amount of 3 mg of D-fagomine has been absorbed (Table 4). The highest excretion rate 209 
occurred in the period  between 2 and 4 h in urine (Figure 2 and Table 5) and in the period between 210 
8 and 24 h in feces (Table 6). D-Fagomine was not detected in feces collected by abdominal 211 
massage 48 h after intake (Table 6). Briefly the absorbed portion of D-fagomine is cleared in urine 212 
within 8 h and the non-absorbed portion in feces within 24 h after intake. The behavior of D-213 
fagomine and DNJ (positive control) was similar (Figure 1 and Tables 4-6) and the absorption 214 
under our experimental conditions reached saturation at a total absorbed amount of 2 mg. As most 215 
(around 90% at the 3 doses) of both of the ingested iminocyclitols is excreted, whether in urine or 216 
feces, within the first 24 h after oral administration these compounds probably do not accumulate in 217 
tissues, as already suggested by Nakagawa et al. (2007) 15.  218 
The results presented here for DNJ agree with two other studies that also used a pure compound 219 
15,18. Nakagawa et al. (2007) 15 found that about 0.6 mg of the DNJ (2%) was excreted in urine 220 
within 24 h after a 110 mg/kg body weight oral administration after fasting 15. Kim et al. (2010) 18221 
reported that about 4 mg of the DNJ administered was excreted in urine within 24 h after a 30 222 
mg/kg body weight oral administration; the non-absorbed fraction was excreted in feces within 48 223 
h. When DNJ was administered as a component of a plant extract, the excretion profile was similar 224 
to that one obtained here. Xiao et al. (2014) reported that about 2.5 mg of DNJ in a mulberry root 225 
bark extract was excreted in urine within the first four hours 27. Our results show that D-fagomine is 226 
absorbed as fast as DNJ is.  227 
Metabolism 228 
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It has been reported that DNJ  (positive control) is mainly excreted in the intact form 15,16,18,27. 229 
Nakagawa et al. (2007) did not detect any degradation products (e.g., oxidized and alkylated 230 
products) in plasma and reported that a small signal in the HPLC-MS single ion monitoring 231 
chromatogram might correspond to an unidentified metabolite 15. We found trace amounts of 232 
monomethyl-DNJ in urine and several methyl derivatives of D-fagomine. A monomethylated 233 
conjugate was present in urine (10%) and feces (3%), at the three doses, within the period of 0-8 h 234 
(Figure 1a, Table 4). We also detected trace levels of dimethyl-D-fagomine and trimethyl-D-235 
fagomine in urine, at the three doses, within the period of 0-8 h. In a preliminary experiment with 236 
samples obtained by administering a higher dose of D-fagomine (250 mg /kg body weight), signals 237 
compatible with deoxygenated products were detected that were not found at the lower 238 
concentrations used here. Metabolism of organic compounds consists mainly of their conversion 239 
into more hydrophilic species that can be readily excreted 28. Phase II conjugation into glucuronides 240 
and sulfates are the most common transformations. Iminocyclitols such as D-fagomine and DNJ are 241 
already highly water soluble and they are rapidly excreted without further modification. 242 
Methylation is a less common phase II conjugation that reduces water solubility and plays the 243 
physiological role of blocking biological activities by modifying chemically active functions, such 244 
as those of amines and hydroxyls 29. In the case of D-fagomine, as only a small percentage is 245 
methylated, it is unlikely that methylation serves the purpose of deactivation. Its structure may 246 
partially fit the requirements for the enzymes involved in the modification of other chemical 247 
species, most likely sugars. The presence of methyl-D-fagomine in feces could be explained by 248 
biliary excretion after modification in the liver. Alternatively, methyl-D-fagomine may be generated 249 
by the gut microbiota as some species of the phylum Actinobacteria are capable of methylating the 250 
terminal units of oligosaccharides 30.   251 
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The presence of intact D-fagomine in urine for several hours after oral ingestion may have 252 
important implications for the maintenance of a healthy status in the urinary tract. The 253 
concentration of D-fagomine in contact with the tissues along the urinary tract for the period of 254 
from 1 to 6 h, in all the rats tested at any dose (Table 5, Figure 2) was higher than the concentration 255 
(10 mg/L) that inhibits adhesion (95%) of Escherichia coli to the intestinal mucosa 7. So, at the 256 
dose that is active at lowering postprandial glucose concentration by 20% (2.0 mg/kg body weight: 257 
the lowest dose tested) D-fagomine may protect against urinary tract infections. D-Fagomine may 258 
also protect the intestinal tract against infections. We recently showed that D-fagomine, at a dose of 259 
23 mg/kg body weight/day, reduced the increase in the population of Enterobacteriales induced by 260 
a high-fat high-sucrose diet 11.    261 
To sum up, orally administered D-fagomine is rapidly absorbed and excreted in urine within 8 h in 262 
rats. The non-absorbed fraction is cleared in feces within 24 h.  D-fagomine is partially methylated 263 
(about 10% in urine and 3% in feces).  The concentration of D-fagomine in urine 1 to 6 h after oral 264 
administration of 2.0 mg/kg body weight is higher than the concentration that inhibits (95%) the 265 
adhesion of E. coli to epithelial surfaces. Therefore, D-fagomine may protect the urinary tract 266 
against infections caused by Enterobacteriales at a dose that is active at reducing postprandial blood 267 
glucose concentration. 268 
269 
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FIGURE CAPTIONS 377 
Figure 1. Percentages of D-fagomine (a) and DNJ (b) including their methyl derivatives, excreted 378 
in feces and urine after oral administration at three different doses.  379 
Figure 2. D-fagomine concentration in urine after oral administration of 2.0 mg/kg body weight. 380 
381 
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Table 1. Cone Voltages and Collision Energies Applied in the ESI-MS/MS Analysis.382 
 Cone voltage (V) Collision energy (V)
DMDP 45 20 
DNJ 45 20 
D-Fagomine 35 20 
Methylfagomine 20 30 
Dimethylfagomine 20 30 
Trimethylfagomine 35 30 
383 
384 
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Table 2. Signal Suppression and Enhancement Effect in Matrix-matched Solutions of Both Urine 385 
and Feces.386 
D-Fagomine/DMDP signal vs D-
fagomine concentration 
DNJ/DMDP signal vs DNJ 
concentration 
Urine Aqueous standards y=0.58x-0.4 y=0.036x-0.06 
Matrix-matched 
standards y=0.099x-0.3 y=0.0018x-0.005 
 SSE (%) 17% (Signal suppression) 5% (Signal suppression) 
Feces Aqueous standards y=0.103x+0.1 y=0.0025x-0.027
Matrix-matched 
standards y=0.47x+1 y=0.010x-0.08 
 SSE (%) 458% (Signal enhancement) 390% (Signal enhancement) 
y relative abundance, x concentration in mg/L or mg/kg, SSE signal suppression enhancement 387 
388 
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Table 3. Identification of D-Fagomine Metabolites by HPLC/ESIHR-TOF-MS.389 
m/z Retention time 
Measured 
mass 
Calculated 
mass Formula ppm Compound 
148 11.7 148.0970 148.0974 C6H14NO3 -2.0 Fagomine 
162 9.4 162.1129 162.1130 C7H16NO3 -0.6 Methylfagomine 
176 12.7 176.1282 176.1287 C8H18NO3 -2.8 Dimethylfagomine 
190 13.3 190.1441 190.1443 C9H20NO3 -1.1 Trimethylfagomine  
Measurements made from a sample of urine collected 1h after administration of D-fagomine (250 390 
mg D-fagomine/kg body weight) during a preliminary pilot study with Sprague-Dawley rats. 391 
392 
393 
394 
395 
396 
397 
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Table 4. Excretion of D-Fagomine and DNJ in Feces and Urine after Oral Administration. 
Compound  
(dose) 
Rat 
mg 
Administere
d 
mg excreted in 
urine (0-8 h), 
intact form 
mg excreted in 
urine (0-8 h), 
methylated form 
mg excreted in 
feces (6-24 h), 
intact form 
mg excreted in 
feces (6-24 h), 
methylated form 
% excreted 
in urine (0-
8 h) 
% excreted 
in feces (6-
24 h) 
Total (% 
feces + 
% urine) 
D-Fagomine 
(2.0 mg/kg body weight) 
1 0.53 0.41 0.04 0.10 - 84 19 103 
2 0.53 0.30 0.03 0.31 0.02 63 64 127 
3 0.57 0.21 0.02 0.39 0.02 41 71 112 
DNJ 
(2.0 mg/kg body weight) 
4 0.72 0.31 - - - 42 - 42 
5 0.80 0.55 - 0.09 - 69 11 80 
6 0.75 0.81 - 0.05 - 108 6 114 
D-Fagomine 
(10 mg/kg body weight) 
7 2.6 0.9 0.08 0.8 0.02 37 30 67 
8 2.7 1.6 0.25 1.6 0.03 70 60 131 
9 2.8 0.5 0.03 1.8 0.10 18 69 87 
DNJ 
(10 mg/kg body weight) 
10 2.6 2.2 - 0.6 - 83 23 105 
11 2.7 1.0 - 2.0 - 38 76 113 
12 2.7 1.6 - 1.1 - 59 42 101 
D-Fagomine 
(100 mg/kg body weight) 
13 26 2.3 0.07 17 0.52 9 66 75 
14 27 1.2 0.03 22 0.53 5 85 90 
15 27 5.4 0.02 18 0.95 20 69 89 
DNJ 
(100 mg/kg body weight) 
16 26 2.4 - 15 - 9 56 65 
17 27 1.4 - 26 - 5 95 101 
18 27 1.7 - 14 - 6 53 60 
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Table 5. D-Fagomine and DNJ Concentration (mg/L) in Urine during Different Periods after Oral 
Administration.
 Rat 0-1 h 1-2 h 2-4 h 4-6 h 6-8 h 8-24 h 
D-Fagomine 
(2.0 mg/kg body weight) 
1 88 100  72 47 ND 
2 33  94 13 traces ND 
3 68  47 ND 17 ND 
DNJ 
(2.0 mg/kg body weight) 
4 160     29 
5 430    280 20 
6 350    160 16 
D-Fagomine 
(10 mg/kg body weight) 
7  410  130 16 ND 
8 620   450  ND 
9 66   65 180 ND 
DNJ 
(10 mg/kg body weight) 
10 580  650 99 33 ND 
11 180  230 42 ND ND 
12 350 640  440 100 ND 
D-Fagomine 
(100 mg/kg body weight)
13  660 380 220 48 <40 
14  730  490 170 <40 
15  2000 360 460 64 <40 
DNJ 
(100 mg/kg body weight)
16   1100  570 <40 
17 240  660 120 63 <40 
18 230 1200 1300 400 90 <40 
ND: Not detected;  collected at the next time point as the animal did not excrete urine during all 
collecting periods. 
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Table 6. D-Fagomine and DNJ Concentration (mg/kg) in Feces Excreted in the 8-24 h Period after 
Oral Administration.
 Rat 6-8 h 8-24 h 48 h 
D-Fagomine 
(2.0 mg/kg body weight) 
1  32 ND 
2 ND 110 ND 
3 ND 170 ND 
DNJ 
(2.0 mg/kg body weight) 
4 ND ND ND 
5 ND 71 ND 
6 ND 34 ND 
D-Fagomine 
(10 mg/kg body weight) 
7  750 ND 
8  450 ND 
9  890 ND 
DNJ 
(10 mg/kg body weight) 
10 ND 150 ND 
11 ND 650 ND 
12  340 ND 
D-Fagomine 
(100 mg/kg body weight) 
13 5000 14000 ND 
14 4000 9200 ND 
15  8500 ND 
DNJ 
(100 mg/kg body weight) 
16 ND 11000 ND 
17 ND 8100 ND 
18  6300 ND 
ND: Not detected;  collected at the next time point as the animal did not excrete feces during all 
collecting periods.
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Figure 2.
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